CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade

It is well established that natural killer (NK) cells can be used as an alternative candidate of T cells for adoptive cell therapy (ACT) due to its high killing capacity, off-the-shelf utility, and low toxicity. Though NK cells provide rapid and potent immune effects, they still suffer from insuffic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Aixian, Du, Yanlin, Wang, Yiru, Zheng, Youshi, Ning, Zhaoyu, Wu, Ming, Zhang, Cuilin, Zhang, Da, Liu, Jingfeng, Liu, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844804/
https://www.ncbi.nlm.nih.gov/pubmed/35228895
http://dx.doi.org/10.1016/j.omtn.2022.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844804/
https://www.ncbi.nlm.nih.gov/pubmed/35228895
http://dx.doi.org/10.1016/j.omtn.2022.01.010

Ejemplares similares